Skip to main content

LCD L37620: MDS FISH

LCD L37620, MDS FISH, is the Local Coverage Determination that Noridian Healthcare Solutions, LLC applies to claims from 13 states plus 3 territories (AK, AS, AZ, CA, GU, HI, ID, MP and others), effective 2025-10-23 and first in force 2019-06-03. The policy text runs 144 words, and its billing and coding article A57661 lists 10 ICD-10-CM codes that support medical necessity for 5 procedure codes. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 10 covered ICD-10-CM codes: the same total as L37602 (Palmetto GBA, 10 codes, revised 2026-01-01) and the same total as L37608 (CGS Administrators, LLC, 10 codes, revised 2026-07-30).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Noridian Healthcare Solutions, LLC
States and territories
16
AK AS AZ CA CNMI GU HI ID MT ND NV OR SD UT WA WY
Revision effective
2025-10-23
Original effective
2019-06-03
Policy text
144 words
Covered ICD-10 codes (articles)
10

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L37620
ContractContractorTypeStates
03201Noridian Healthcare Solutions, LLCA and B MACMT
03301Noridian Healthcare Solutions, LLCA and B MACND
03401Noridian Healthcare Solutions, LLCA and B MACSD
03501Noridian Healthcare Solutions, LLCA and B MACUT
03601Noridian Healthcare Solutions, LLCA and B MACWY
03102Noridian Healthcare Solutions, LLCA and B MACAZ
03202Noridian Healthcare Solutions, LLCA and B MACMT
03302Noridian Healthcare Solutions, LLCA and B MACND
03502Noridian Healthcare Solutions, LLCA and B MACUT
03602Noridian Healthcare Solutions, LLCA and B MACWY
03402Noridian Healthcare Solutions, LLCA and B MACSD
03101Noridian Healthcare Solutions, LLCA and B MACAZ
02201Noridian Healthcare Solutions, LLCA and B MACID
02101Noridian Healthcare Solutions, LLCA and B MACAK
02301Noridian Healthcare Solutions, LLCA and B MACOR
02401Noridian Healthcare Solutions, LLCA and B MACWA
02202Noridian Healthcare Solutions, LLCA and B MACID
02102Noridian Healthcare Solutions, LLCA and B MACAK
02402Noridian Healthcare Solutions, LLCA and B MACWA
02302Noridian Healthcare Solutions, LLCA and B MACOR
01111Noridian Healthcare Solutions, LLCA and B MACCA
01211Noridian Healthcare Solutions, LLCA and B MACAS CNMI GU HI
01311Noridian Healthcare Solutions, LLCA and B MACNV
01911Noridian Healthcare Solutions, LLCA and B MACAS CA CNMI GU HI NV
01112Noridian Healthcare Solutions, LLCA and B MACCA
01182Noridian Healthcare Solutions, LLCA and B MACCA
01212Noridian Healthcare Solutions, LLCA and B MACAS CNMI GU HI
01312Noridian Healthcare Solutions, LLCA and B MACNV

Billing and coding article A57661: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57661 (Billing and Coding: MDS FISH) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A57661: Billing and Coding: MDS FISH (Billing and Coding, effective 2025-10-23)

Covered ICD-10-CM codes
10
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
5
Full article
cms.gov record
First 10 covered ICD-10-CM codes in A57661
ICD-10-CMDescription (FY2027)
C94.6Myelodysplastic disease, not elsewhere classified
D46.0Refractory anemia without ring sideroblasts, so stated
D46.1Refractory anemia with ring sideroblasts
D46.20Refractory anemia with excess of blasts, unspecified
D46.21Refractory anemia with excess of blasts 1
D46.22Refractory anemia with excess of blasts 2
D46.ARefractory cytopenia with multilineage dysplasia
D46.BRefractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.ZOther myelodysplastic syndromes

Procedure codes: 88271, 88273, 88274, 88275, 88291.

Coverage indications, limitations and medical necessity

This policy provides coverage for indicated fluorescent in situ hybridization (FISH) probes for patients whose bone marrow examination is suggestive of myelodysplasia (MDS) and who have an inadequate cytogenetic assessment by conventional karyotyping. In general, conventional karyotype analysis is sufficient for confirmation for the diagnosis of MDS. MDS FISH studies should only be performed when there are fewer than 20 metaphases available for analysis, or an unresolved karyotype. Medicare will only cover up to 4 FISH studies (-7 or del(7q), -5 or del(5q), +8 and del(20q)) on initial evaluation to diagnose MDS. Reflex testing for additional FISH markers to diagnose MDS is only reasonable and necessary when the initial 4 studies are negative, or the diagnosis remains uncertain following the initial 4 probes.

Generally, FISH testing is not reasonable and necessary for diagnosing MDS and provides little if any additional information to conventional karyotyping.

Summary of evidence (opening)

The myelodysplastic syndromes (MDS) represent a spectrum of clonal bone marrow diseases with heterogeneous presentations. The classic triad for MDS includes 1 or more cytopenias, defective differentiation (dysplasia) of 1 or more blood cell lines and marrow hypercellularity. Over time, there is an increased rate of progression to acute myeloid leukemia (AML). These secondary AML cases carry a worse prognosis than de novo AML cases. Furthermore, there are myeloid neoplasms that share overlapping characteristics with both MDS and myeloproliferative neoplasms (MPNs), such as chronic myelomonocytic leukemia (CMML). The World Health Organization (WHO) has designated these diseases separately as MDS/MPNs, distinct from either MDS or MPNs. (1)

According to the 2016 National Comprehensive Cancer Network (NCCN) Guidelines, the overall incidence of MDS is approximately 5/100,000 per year, primarily in adults. MDS is rare in patients under the age of 40, but much more common in older patients. The incidence of MDS among patients 70-79 years of age is 30/100,000, and in patients > 80 years the incidence is 60/100,000. (2)

MDS has historically been classified by a combination of traditional laboratory techniques, such as demonstration of stable cytopenias by complete blood count, microscopic examination of a bone marrow biopsy, and bone marrow cytogenetic (conventional karyotype) studies. Other than the clinical feature of the number of cytopenias and specific cytogenetic changes found recurrently in MDS, all other diagnostic criteria in MDS rely upon light microscopy findings. These include the dysplastic changes on 1 or more cell lineages of megakaryocytes, erythrocytes and granulocytes; increased myeloblasts; and/or presence of ringed sideroblasts. Low-risk MDS is associated with dysplasia affecting only 1 cell lineage, with or without ringed sideroblasts, and isolated deletions involving the long arm of chromosome 5 (5q-). High-risk disease is associated with dysplasia across multiple lineages, increased blast percentages, and complex karyotype.

Neither the 2016 WHO Classification of MDS, the International Prognostic Scoring System (IPSS) nor the Revised IPSS (IPSS-R) require the use of additional MDS-associated mutations to establish a diagnosis of MDS. As noted in NCCN 2017 Guidelines, “Bone marrow or peripheral blood cells may be assayed for MDS-associated gene mutations. These can establish the presence of clonal hematopoiesis which can help exclude benign causes of cytopenia with non-diagnostic morphology but do not establish the diagnosis of MDS in the absence of clinical diagnostic criteria.”

The contractor cites 8 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2019-06-03
Current revision effective
2025-10-23
Last reviewed by the contractor
2022-05-09
MCD version
16

Other related documents: A56446 (Response to Comments), A56447 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Noridian Healthcare Solutions, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L37620 cover?

This policy provides coverage for indicated fluorescent in situ hybridization (FISH) probes for patients whose bone marrow examination is suggestive of myelodysplasia (MDS) and who have an inadequate cytogenetic assessment by conventional karyotyping. In general, conventional karyotype analysis is sufficient for confirmation for the diagnosis of MDS. MDS FISH studies should only be performed when there are fewer… The full 144-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L37620 apply to?

Noridian Healthcare Solutions, LLC applies it to Medicare claims in 13 states plus 3 territories: AK, AS, AZ, CA, GU, HI, ID, MP, MT, ND, NV, OR, SD, UT, WA, WY. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L37620?

The companion billing and coding article A57661 lists 10 ICD-10-CM codes in 1 group that support medical necessity; the first 10 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L37620?

A denial under LCD L37620 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57661's 10 covered diagnosis codes, then file a redetermination with Noridian Healthcare Solutions, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.